| Drug | Clinical isolates | Clinical specimens | ||
| MTBDRsl | DST | MTBDRsl | DST | |
| Fluoroquinolones | ||||
| Sensitivity | 99.4 (96.8–99.9) | 73.7 (61.0–83.4) | 94.9 (86.1–98.3) | 100 (64.6–100) |
| Specificity | 99.2 (95.3–99.9) | 100 (92.7–100) | ||
| PPV | 97.7 (87.9–99.6) | 100 (64.6–100) | ||
| NPV | 88.6 (82.0–92.9) | 100 (92.7–100) | ||
| Likelihood ratio pos. | 86.2 (11.9–62.2) | Undefined | ||
| Likelihood ratio neg. | 0.3 (0.2–0.3) | 0 | ||
| Diagnostic accuracy | 90.8 (85.6–94.3) | 100 (93.6–100) | ||
| Second-line injectable drugs | ||||
| Sensitivity | 99.4 (96.8–99.9) | 71.4 (61.2–80.0) | 91.5 (81.7–96.3) | 87.5 (52.9–97.8) |
| Specificity | 100 (95.9–100) | 89.1 (77.0–95.3) | ||
| PPV | 100 (94.0–100) | 58.3 (32.0–80.7) | ||
| NPV | 79.0 (70.6–85.4) | 97.6 (87.7–99.6) | ||
| Likelihood ratio pos. | Undefined | 8.1 (5.2–12.4) | ||
| Likelihood ratio neg. | 0.3 (0.3–0.3) | 0.1 (0.02–1.0) | ||
| Diagnostic accuracy | 86.2 (80.3–90.6) | 88.8 (77.8–94.8) | ||
| Ethambutol# | ||||
| Sensitivity | 99.4 (96.8–99.9) | 69.7 (61.0–77.1) | 94.9 (86.1–98.3) | 86.1 (71.3–93.9) |
| Specificity | 96.2 (87.0–98.9) | 100 (83.9–100) | ||
| PPV | 97.7 (92.0–99.4) | 100 (87.9–100) | ||
| NPV | 57.5 (47.0–67.3) | 80.0 (60.9–91.1) | ||
| Likelihood ratio pos. | 18.1 (6.7–47.8) | Undefined | ||
| Likelihood ratio neg. | 0.3 (0.3–0.3) | 0.1 (0.09–0.2) | ||
| Diagnostic accuracy | 77.6 (70.8–83.2) | 91.1 (80.7–96.1) | ||
Data are presented as % (95% CI %). DST: drug-susceptibility testing; interval; PPV: positive predictive value; NPV: negative predictive value; pos: positive; neg: negative; inject: injectable. #: the phenotypic DST result is adjusted according to the minimum inhibitory concentration results.